AmericanPeptide sells nothing. It reads what each vendor actually publishes and ranks them by one thing: the provenance tier of the purity claim. An independent, per-batch COA backs a third-party claim; a vendor’s own number backs a vendor-reported one. Same scale as the chemistry, the monographs, and everything else here — the Standard.
37 compounds with a ranked field of sources
GLP-1 / GIP / glucagon agonists and adipose-targeting peptides.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
Investigational once-weekly triple agonist (GIP / GLP-1 / glucagon) — the molecule some in the research community nickname "GLP-3" — with the largest weight reductions reported for any incretin-class agent.
Long-acting amylin analog — Novo Nordisk’s answer to GLP-1 from a second satiety pathway, studied alone and as half of CagriSema. Phase 3 monotherapy reported ~11.8% mean weight loss.
C-terminal hGH fragment (177–191) historically investigated for lipolysis.
Small-molecule NNMT inhibitor (often catalogued alongside peptides).
GHRH analogs, GHRPs, and growth hormone secretagogues.
A splice variant of IGF-1 expressed after muscle damage; studied for satellite-cell activation.
Modified GHRH(1-29) analog with short plasma half-life.
Long-acting GHRH analog with a Drug Affinity Complex for albumin binding.
Selective ghrelin receptor agonist (GHRP) with minimal cortisol / prolactin release.
GHRH analog FDA-approved for HIV-associated lipodystrophy.
Truncated GHRH(1-29) — historically the first GHRH analog approved by the FDA.
Synthetic hexapeptide GHRP with potent GH-releasing activity.
Second-generation synthetic GHRP; a potent ghrelin-receptor agonist approved in Japan as a diagnostic for GH deficiency.
An orally active, non-peptide ghrelin-receptor agonist and growth-hormone secretagogue — a small molecule catalogued alongside the GH peptides.
Tissue repair, angiogenesis, and regenerative peptides.
Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
Synthetic fragment of thymosin β4 studied for cell migration and tissue repair.
An 11-amino-acid, non-erythropoietic fragment of erythropoietin that keeps EPO’s tissue-protective, anti-inflammatory activity without raising red blood cells.
Nootropics, neurotrophics, and synaptic modulators.
Russian synthetic ACTH(4-10) analog studied for nootropic and neuroprotective effects.
Synthetic heptapeptide analog of tuftsin investigated as an anxiolytic.
Endogenous nonapeptide first isolated for its sleep-promoting properties.
An orally active angiotensin IV–derived peptidomimetic reported as an extraordinarily potent synaptogenic (synapse-forming) compound.
Senolytics, telomere, and aging-axis peptides.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
A senolytic D-retro-inverso peptide that selectively triggers apoptosis in senescent cells by disrupting the FOXO4–p53 interaction.
Pigmentation, hair, and skin-targeting peptides.
HPG-axis, kisspeptin, and reproductive hormones.
Thymic peptides and immunomodulators.
Thymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
A synthetic thymic dipeptide (Glu-Trp) immunomodulator — the minimal active fragment distilled from thymus peptides.
Thymus-derived 28-amino-acid peptide approved in many countries as an immunomodulator.
Human cathelicidin antimicrobial peptide active across bacteria, fungi, and viruses.
Anti-inflammatory C-terminal tripeptide of α-MSH.
Mitochondrial bioenergetics and NAD+ axis.
Mitochondrially-encoded peptide with reported insulin-sensitizing activity.
Mitochondria-targeted cardiolipin-binding tetrapeptide.
Essential redox cofactor central to mitochondrial bioenergetics and sirtuin activity.
Short peptide bioregulators (Khavinson peptides) — tissue-specific gene-regulatory peptides.